Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 181

1.

Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.

Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP.

J Am Coll Cardiol. 2012 Dec 18;60(24):2504-12. doi: 10.1016/j.jacc.2012.07.068. Epub 2012 Nov 14.

2.

Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.

Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, Allen LA, Nekhlyudov L, Goddard KA, Davis RL, Habel LA, Yood MU, McCarty C, Magid DJ, Wagner EH; Pharmacovigilance Study Team..

J Natl Cancer Inst. 2012 Sep 5;104(17):1293-305. doi: 10.1093/jnci/djs317.

3.

Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.

Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH.

J Clin Oncol. 2007 Sep 1;25(25):3808-15. Epub 2007 Jul 30.

PMID:
17664460
4.

Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998-2005.

Du XL, Xia R, Burau K, Liu CC.

Med Oncol. 2011 Dec;28 Suppl 1:S80-90. doi: 10.1007/s12032-010-9717-7. Epub 2010 Oct 22.

PMID:
20967512
5.

Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure.

Seicean S, Seicean A, Alan N, Plana JC, Budd GT, Marwick TH.

Circ Heart Fail. 2013 May;6(3):420-6. doi: 10.1161/CIRCHEARTFAILURE.112.000055. Epub 2013 Feb 20.

6.

The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study.

Goldhar HA, Yan AT, Ko DT, Earle CC, Tomlinson GA, Trudeau ME, Krahn MD, Krzyzanowska MK, Pal RS, Brezden-Masley C, Gavura S, Lien K, Chan KK.

J Natl Cancer Inst. 2015 Oct 16;108(1). pii: djv301. doi: 10.1093/jnci/djv301. Print 2016 Jan.

PMID:
26476433
7.

Risk of cardiovascular adverse events from trastuzumab (Herceptin(®)) in elderly persons with breast cancer: a population-based study.

Tsai HT, Isaacs C, Fu AZ, Warren JL, Freedman AN, Barac A, Huang CY, Potosky AL.

Breast Cancer Res Treat. 2014 Feb;144(1):163-70. doi: 10.1007/s10549-014-2836-7. Epub 2014 Jan 28.

8.

Lack of uniformity in cardiac assessment during trastuzumab therapy.

Subar M, Lin W, Chen W, Pittman DG.

Breast J. 2011 Jul-Aug;17(4):383-90. doi: 10.1111/j.1524-4741.2011.01101.x. Epub 2011 May 27.

PMID:
21615821
9.

[Heart failure in women treated with adjuvant trastuzumab for breast cancer].

Tarantini L, Feola M, Albini A, Gori S, Foglietta J, Cicoira MA, Pulignano G.

G Ital Cardiol (Rome). 2012 May;13(5 Suppl 1):54S-62S. Italian.

PMID:
23678535
10.

Trastuzumab-induced cardiotoxicity in elderly women with HER-2-positive breast cancer: a meta-analysis of real-world data.

Leung HW, Chan AL.

Expert Opin Drug Saf. 2015;14(11):1661-71. doi: 10.1517/14740338.2015.1089231. Epub 2015 Oct 13.

PMID:
26461271
11.

Cardiotoxic effects of trastuzumab.

Hysing J, Wist E.

Tidsskr Nor Laegeforen. 2011 Nov 15;131(22):2239-41. doi: 10.4045/tidsskr.10.0862. Review. English, Norwegian.

12.

Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study.

Sawaki M, Mukai H, Tokudome N, Nakayama T, Taira N, Mizuno T, Yamamoto Y, Horio A, Watanabe T, Uemura Y, Ohashi Y.

Breast Cancer. 2012 Jul;19(3):253-8. doi: 10.1007/s12282-011-0270-9. Epub 2011 Apr 28.

PMID:
21526424
13.

Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?

Castrellon AB, Glück S.

Clin Adv Hematol Oncol. 2008 Sep;6(9):666-72.

PMID:
18827789
14.

Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer.

Du XL, Xia R, Liu CC, Cormier JN, Xing Y, Hardy D, Chan W, Burau K.

Cancer. 2009 Nov 15;115(22):5296-308. doi: 10.1002/cncr.24621. Erratum in: Cancer. 2009 Dec 15;115(24):5849-51.

15.
16.

Cardiac safety of trastuzumab as adjuvant treatment for Japanese patients with early breast cancer.

Ishihara M, Mukai H, Nagai S, Mukohara T.

Int J Clin Oncol. 2009 Oct;14(5):431-5. doi: 10.1007/s10147-009-0898-z. Epub 2009 Oct 25.

PMID:
19856052
17.

Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.

Griffiths RI, Barron RL, Gleeson ML, Danese MD, O'Hagan A, Chia VM, Legg JC, Lyman GH.

Pharmacoeconomics. 2012 Feb 1;30(2):103-18. doi: 10.2165/11589440-000000000-00000.

PMID:
21967155
18.

Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.

Baselga J, Perez EA, Pienkowski T, Bell R.

Oncologist. 2006;11 Suppl 1:4-12. Review.

19.

Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer.

Tarantini L, Cioffi G, Gori S, Tuccia F, Boccardi L, Bovelli D, Lestuzzi C, Maurea N, Oliva S, Russo G, Faggiano P; Italian Cardio-Oncologic Network..

J Card Fail. 2012 Feb;18(2):113-9. doi: 10.1016/j.cardfail.2011.10.015. Epub 2011 Dec 3.

PMID:
22300778
20.

Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study.

Seicean S, Seicean A, Plana JC, Budd GT, Marwick TH.

J Am Coll Cardiol. 2012 Dec 11;60(23):2384-90. doi: 10.1016/j.jacc.2012.07.067. Epub 2012 Nov 7.

Supplemental Content

Support Center